secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2025-06-10T23:59:59+00:00
Accession:  0001125345-25-000087
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics sells ZYNYZ royalty rights to Sagard for $70M; cash runway extended into H1 2027
--------------------------------------------------------------------------------

- Received $70M upfront from Sagard for capped royalty on global net sales of ZYNYZ (retifanlimab-dlwr).
- After Sagard collects $140M in royalties (2.0x), MacroGenics resumes all future royalty payments.
- MacroGenics retains other ZYNYZ economic interests, including development and commercial milestones.
- Cash, equivalents and securities were $154.1M at March 31, 2025; combined with $70M, runway now through first half 2027.
- ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte in 2017.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000087/0001125345-25-000087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534525000087/mgnx-20250609.htm
  HTML page:      https://secwatch.observer/filing/0001125345-25-000087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer